Changeflow GovPing Pharma & Drug Safety PARP1 Inhibitors and Uses Thereof
Routine Notice Added Final

PARP1 Inhibitors and Uses Thereof

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO published patent application US20260098024A1 disclosing PARP1 inhibitor compounds and pharmaceutical compositions for cancer treatment. The application, filed on January 26, 2023 under application number 18833362, names six inventors including Robert L. Hoffman and Stephen W. Kaldor and covers compounds classified under C07D 401/12 and C07D 471/04.

What changed

USPTO published patent application US20260098024A1 disclosing novel PARP1 (poly ADP-ribose polymerase 1) inhibitor compounds and pharmaceutical compositions comprising said inhibitors for treating cancer. The application covers compounds classified under CPC subclasses C07D 401/12 and C07D 471/04, with claims directed to the inhibitor compounds, pharmaceutical formulations, and methods of treatment.

Pharmaceutical companies developing PARP inhibitors or cancer therapeutics should review the published claims to assess freedom-to-operate considerations. Competitors in the oncology drug development space should monitor this application and related filings for potential blocking patents. Research institutions and clinical investigators may find this IP landscape relevant for partnership or licensing discussions.

What to do next

  1. Monitor for patent grant status
  2. Conduct freedom-to-operate analysis for PARP1 inhibitor development
  3. Review published claims for competitive implications

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PARP1 INHIBITORS AND USES THEREOF

Application US20260098024A1 Kind: A1 Apr 09, 2026

Inventors

Robert L. Hoffman, Porino Jinjo Va, Joseph Robert Pinchman, Lynnie Trzoss, Qing Dong, Stephen W. Kaldor

Abstract

Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

CPC Classifications

C07D 401/12 A61K 31/496 A61K 31/498 A61P 35/00 C07D 471/04

Filing Date

2023-01-26

Application No.

18833362

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260098024A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing Clinical trials
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Product Safety

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.